Genematrix

Genematrix Assets per Share

The Total Assets per Share of Genematrix (109820.KQ) as of Oct 26, 2026 is 1,366.01 KRW. In the previous year, Total Assets per Share was 1,425.47 KRW — a change of -4.17% (lower).

Assets per Share

1,366.01KRW

YoY

-4.17%

Last updated:

Total Assets per Share of Genematrix is 2025 1,366.01 KRW. Total Assets per Share of Genematrix was 2024 1,425.47 KRW. It decreases by -4.17% lower compared to the previous year.

The Genematrix Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2018
1,578.76 KRW
Jan 1, 2019
1,425.34 KRW
Jan 1, 2020
1,911.81 KRW
Jan 1, 2021
1,980.15 KRW
Jan 1, 2022
1,597.98 KRW
Jan 1, 2023
1,570.51 KRW
Jan 1, 2024
1,425.47 KRW
Jan 1, 2025
1,366.01 KRW
The Genematrix Assets per Share history
YEARAssets per ShareYoY
1,366.01KRW-4.17%
1,425.47KRW-9.24%
1,570.51KRW-1.72%
1,597.98KRW-19.30%
1,980.15KRW+3.57%
1,911.81KRW+34.13%
1,425.34KRW-9.72%
1,578.76KRW+77.64%
888.76KRW-8.23%
968.43KRW-6.97%
1,040.96KRW+21.88%
854.05KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genematrix Stock analysis

What does Genematrix do? Genematrix Inc develops RFMP genotyping technology for diagnosing hepatitis B virus (HBV), hepatitis C virus (HCV), and human papillomavirus (HPV) within its pharmaceutical development segment. The company manufactures and sells liver-function examination reagents through its diagnostic medicine segment, while also importing and selling medical equipment and reagents. Customers for these products include healthcare providers and medical facilities requiring viral diagnostics and liver function testing. The pharmaceutical development segment targets laboratories focused on viral infection diagnosis, while the diagnostic medicine segment serves hospitals and clinics needing reagents for liver health assessments. Genematrix Inc's revenue streams come from sales of RFMP-based diagnostic tools for HBV, HCV, and HPV testing, alongside liver-function reagent sales. The company's diagnostic medicine segment generates income through the import and sale of medical equipment and reagents, catering to healthcare institutions. Its pharmaceutical development segment focuses on viral genotyping solutions for medical laboratories, creating a dual revenue model from both diagnostic products and equipment services. The company's products are sold to healthcare institutions requiring viral diagnostics and liver function testing. Pharmaceutical development customers include medical laboratories specializing in HBV, HCV, and HPV testing, while diagnostic medicine customers are hospitals and clinics using liver-function reagents. Genematrix Inc's business model relies on direct sales of its proprietary RFMP technology and imported medical equipment to these specialized healthcare segments without third-party distribution. Genematrix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genematrix stock

Total Assets per Share of Genematrix is 1,366.01 KRW in 2025.

Total Assets per Share of Genematrix changed from 1,425.47 KRW to 1,366.01 KRW, representing a -4.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share Genematrix since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Genematrix

All Key Metrics — Genematrix